SM
BCTXL

Sabby Management’s BriaCell Therapeutics Warrant BCTXL Stock Holding History

Sabby Management’s Portfolio BCTXL Stock Details BCTXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$169K Sell
190,383
-190,303
-50% -$176K 0.15% 19
2026
Q1 		$392K Buy
+380,686
New +$403K 0.87% 7

Other funds holding BCTXL

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
MA
MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Sabby Management's BCTXL Position: Q2 2026 in Review

Sabby Management reduced its BriaCell Therapeutics Warrant (BCTXL) stake by 50% in Q2 2026, selling an estimated $176K and leaving 190,383 shares worth $169K. The position accounts for 0.15% of the portfolio, ranked #19.

Sabby Management first reported a position in BCTXL in Q1 2026 and has held it in 2 quarters since. The position peaked at $392K in Q1 2026. 10 funds tracked by Wall St. Rank hold BCTXL as of Q2 2026.

  • Sabby Management held 190,383 shares of BriaCell Therapeutics Warrant worth $169K as of Q2 2026.
  • Sabby Management sold 190,303 BriaCell Therapeutics Warrant shares in Q2 2026, an estimated $176K.
  • BriaCell Therapeutics Warrant made up 0.15% of Sabby Management's portfolio in Q2 2026, its #19 holding.
  • Sabby Management first reported a position in BriaCell Therapeutics Warrant in Q1 2026 and has held it in 2 quarters since.
  • Sabby Management's BriaCell Therapeutics Warrant position peaked at $392K in Q1 2026.
  • 10 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant as of Q2 2026.

Based on Sabby Management's 13F filing for Q2 2026, filed 14 Aug 2026.